- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The Global Plan provides an opportunity for greater alignment among efforts to fight both diseases. Taking inspiration from the UNAIDS target of providing treatment to 90% of people who know their HIV-positive status, the Global Plan calls for countries to find at least 90% of all people with TB in the population that require treatment (including those living with HIV) and place them on appropriate therapy (including TB treatment and preventive therapy for people living with HIV).
Tuberculosis (TB) remains the largest cause of death and suffering due to any communicable disease among the most productive groups in the World Health Organization’s South-East Asia Region (SEAR). Nearly half of global TB cases emerge in this Region, which is home to one fourth of the total population. It is estimated that TB and TB-HIV co-infection caused 3 deaths every 2 minutes in the Region in 2015. These deaths were entirely preventable with proper treatment of all TB patients, including those infected with drug-resistant strains.
The WHO End TB strategy and corresponding Regional Strategic Plan to end TB targets reductions to the extent of 90% in deaths, and 80% in TB incidence by 2030. This is in alignment with the Sustainable Development Goals (SDGs) to which all countries have committed.
Out of Step includes the results of a 29-country survey on national TB policies and practices. The report was created to identify gaps in implementation and monitor progress towards ending TB.
While countries have made progress since the 2015 Out of Step report, much more work needs to be done to make sure that these policies are fully implemented across all communities, so that they will make a real difference to people affected by TB.
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO’s Member States and broader development goals set by the United Nations.
Keywords: SDGs, TB, ART, treatment, prevention, diagnosis
Unitaid invests in new ways to prevent, diagnose and treat tuberculosis (TB) more quickly, more cheaply and more effectively. Some of our interventions include: accelerating diagnosis. The most widely used test for TB is to take a patient’s sputum sample and identify the bacterium under a microscope. The bacteria are then grown in a dish containing anti-TB drugs to see if they are resistant to the most commonly used drugs to treat TB.
This document aims to articulate a coherent vision of the research needs to end TB and elaborates on the funding and structural requirements that are necessary to operationalize this vision. It describes how some of the research funded in the past has delivered benefits to patients and influenced policy- and decision-making, but also how little is being invested in TB R&D in comparison with other diseases, such as HIV and malaria, that also affect poor populations. The paper shows that, despite significant progress, previous investments were not sufficient to warrant success in tackling difficult challenges, such as multidrug-resistant TB (MDR-TB), expedited development of new and improved tools, and effective deployment of such tools.
National Tuberculosis Programme (NTP) is functioning with Regional/State TB centers and 101 vertical TB teams. The NTP covered all 325 townships with DOTS strategy in November 2003 and all 330 townships including five new townships established in NayPyiTaw Union Territory in 2011. "Stop TB Strategy" was introduced in 2007 aiming to achieve the targets linked to the Millennium Development Goals (MDGs) by 2015.
The world’s 370 million indigenous peoples face a plethora of issues caused by displacement, dispossession, loss of livelihood, systematic racism and abuse, and lack of recognition (1–4). Further hindering an adequate response to these challenges, there is a pervasive lack of data about indigenous peoples concerning health and other key development indicators. Data that are available show a prevalence of extreme poverty and severe health disparities that include tuberculosis (TB).
Keywords: TB, health, diagnosis, treatment, data
This report is the first in a series produced by the Stop TB Partnership. The goal is to assess the status of country TB programmes in terms of the Global Plan’s 90-(90)-90 targets and to provide a baseline for monitoring progress over the next 5 years. Currently, the 30 high TB and drug-resistant TB (DR-TB) burden countries that account for almost 80% of the global burden exhibit the biggest gaps in the areas of diagnosis for TB and DR-TB, and the provision of preventive therapy (PT). Moreover, monitoring the uptake of TB services in key populations remains a challenge due to the limited availability and disaggregation of data.
The World Health Organization (WHO) and UNICEF has issued a joint statement, urging all National TB Programmes to replace the previously used medicines for children weighing less than 25 kg with the child-friendly dispersible TB fixed-dose combinations (FDCs) at the soonest possible time. WHO and UNICEF advise against continued usage of the old sub-optimally dosed FDCs or adult formulations (crushed tablets), which may lead to under or over-dosing, unfavourable treatment outcomes, and high likelihood of contributing to the development of drug resistance.